Literature DB >> 9607845

Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.

N Lendvai1, A Casadevall, Z Liang, D L Goldman, J Mukherjee, L Zuckier.   

Abstract

Cryptococcus neoformans is an encapsulated opportunistic fungus that can cause chronic infections accompanied by high tissue levels of capsular polysaccharide (CPS). CPS or its major component, glucuronoxylomannan (GXM), was administered to mice, and whole-body and tissue levels were measured. The role of monoclonal antibody (MAb), complement, and CD4 T cells in GXM clearance was also examined. These studies demonstrate that CPS is cleared from the blood within days but is retained in the body for weeks; that MAbs of all isotypes examined promote GXM clearance; that MAb-mediated GXM deposition in liver, but not in spleen, is Fc-dependent; that complement enhances IgM-mediated GXM sequestration in liver but not spleen; and that CD4 T cells are not necessary for serum GXM clearance. The results have important implications for the eventual use of MAbs in treatment of cryptococcosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607845     DOI: 10.1086/515329

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.

Authors:  Zong Liang Chang; Dale Netski; Peter Thorkildson; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection.

Authors:  J Rivera; M Feldmesser; M Cammer; A Casadevall
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

3.  Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo.

Authors:  Lauren E Yauch; Michael K Mansour; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.

Authors:  D O Beenhouwer; S Shapiro; M Feldmesser; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cells.

Authors:  Johanna Rivera; Oscar Zaragoza; Arturo Casadevall
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

6.  Expression of a Mycobacterium tuberculosis arabinomannan antigen in vitro and in vivo.

Authors:  J R Schwebach; A Casadevall; R Schneerson; Z Dai; X Wang; J B Robbins; A Glatman-Freedman
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

7.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.

Authors:  Suzanne Brandt; Peter Thorkildson; Thomas R Kozel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

Review 9.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

10.  Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan.

Authors:  Kausik Datta; Andrew Lees; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2008-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.